Direct-to-Consumer Lab Testing: A Clinician's Field Guide

Five years ago, patients brought printouts from WebMD. Today, they bring 100-biomarker lab panels they ordered themselves. Function Health alone has processed over 2 million tests since launch. This is not a trend — it's a permanent shift in how patients engage with their own health data.

The Landscape

Three categories of DTC lab services:

Comprehensive panels (Function Health, Life Extension): 100+ biomarkers including metabolic, hormonal, inflammatory, and genetic markers. $499-999/year. Most thorough but hardest to interpret without clinical context.

Targeted wellness (InsideTracker, Everlywell): 10-30 biomarkers focused on optimization. $99-299 per panel. Often includes AI-generated recommendations that may conflict with clinical guidance.

At-home collection (LetsGetChecked, Paloma Health): Finger-prick or saliva collection mailed to a CLIA lab. Convenient but more variable on pre-analytical quality.

What to Do When Patients Bring Their Own Data

1. Don't dismiss it

The fastest way to lose a patient's trust is to wave away data they paid $500 for. Even if the results are clinically insignificant, the act of ordering those tests tells you something important about the patient's health anxiety, motivation, and engagement level.

2. Validate the source

Not all DTC labs are equal. Ask: Which lab processed it? Is it CLIA-certified? Was collection supervised or at-home? Fasting or non-fasting? These factors affect interpretation significantly.

3. Focus on trends, not snapshots

A single testosterone level of 380 ng/dL tells you almost nothing. Three readings over 6 months showing a declining trend is clinically relevant. Teach patients to track trends, not panic over single values.

4. Set boundaries on scope

You are not obligated to interpret every biomarker on a 100-panel test. It is reasonable to say: "I'll review the results relevant to your health concerns today, and we can schedule a follow-up for the remaining items."

5. Document carefully

If a patient shows you DTC lab results and you review them, that review becomes part of the clinical encounter. Document what you reviewed, what you advised, and — critically — what you chose not to act on and why.

The Liability Question

The legal risk is not in reviewing DTC data — it's in ignoring it. If a patient brings you a lab result showing a significantly abnormal value and you dismiss it without documentation, you've created a liability gap. The standard of care is evolving to include patient-sourced data.

Billing Considerations

You can bill for the time spent interpreting patient-provided lab data. Use established E/M codes — the data review contributes to medical decision-making complexity. Document the time spent and the clinical relevance.

The Bottom Line

DTC lab testing is not going away. The physicians who thrive will be the ones who learn to incorporate patient-sourced data into their workflow — not fight it. The data quality is improving, the patient demand is growing, and the regulatory environment is adapting.

Your job is not to be the gatekeeper of lab data anymore. It's to be the interpreter.